Research programme: ophthalmic norketotifen - Sirion Therapeutics
Alternative Names: Topical ophthalmic norketotifenLatest Information Update: 16 Jul 2016
At a glance
- Originator Bridge Pharma
- Developer Sirion Therapeutics
- Class
- Mechanism of Action Mast cell stabilisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in USA (Ophthalmic)
- 20 Feb 2008 Preclinical trials in Eye disorders in USA (Ophthalmic)